Feds buy more monoclonal treatment that fights omicron
The U.S. government is buying 600,000 more doses of sotrovimab, the only the monoclonal antibody treatment expected to hold up against omicron, according to the drug makers, GlaxoSmithKline and Vir Biotechnology.
These doses are set to be delivered to the government over the next two months, the drug makers said.
This brings total sotrovimab doses purchased by the federal government to approximately 1 million.
Short supply of sotrovimab has been a growing concern for the White House as omicron spreads.
Until recently the government had not invested in buying bulk stock of sotrovimab, as it has with other monoclonal treatments. The government spent billions buying Regeneron and Eli Lilly's products to ensure there would be enough supply, but both of those may not hold up against omicron.
-ABC News' Sasha Pezenik